Dupilumab restores skin barrier in young children with AD

Child with Atopic Dermatitis Photo by Eisfelder via Wikimedia Commons

A new study shows that treatment with dupilumab significantly restores skin barrier function and reduces inflammation in children aged 6 to 11 years with moderate-to-severe atopic dermatitis (AD). Researchers found improvements not only in visible AD lesions but also in clinically unaffected skin, highlighting the systemic nature of the disease.

The findings were published in Annals of Allergy, Asthma & Immunology.

“Atopic dermatitis is not just a surface rash. It is a chronic inflammatory disease driven by immune dysfunction and a compromised skin barrier,” said senior author Donald Leung, MD, PhD, in a press release from National Jewish Health. “Our study demonstrates that dupilumab helps normalize the skin barrier in children, including areas of skin that appear clinically unaffected. These findings suggest we may be addressing the underlying disease process, not just treating symptoms.”

Dr. Leung is director of the Food Allergy & Asthma Program at National Jewish Health in Denver.

Researchers evaluated skin barrier function using transepidermal water loss and optical coherence tomography. At baseline, children with atopic dermatitis had significantly higher transepidermal water loss and thicker epidermis in both lesional and non-lesional skin compared with healthy controls, indicating widespread barrier dysfunction and inflammation.

“These objective, noninvasive tools allowed us to see that dupilumab not only improves what we can observe clinically but also repairs deeper structural and functional abnormalities in the skin,” Dr. Leung said.

“Repairing the skin barrier early in life may have important implications for preventing progression to other allergic conditions,” he said. “Childhood represents a critical window of opportunity when the immune system is still highly adaptable.”

Dupilumab was generally well-tolerated. No serious or severe adverse events occurred with treatment, and none led to treatment discontinuation.